Pelthos Therapeutics PTHS
NYSE PTHS
$21.50 +0.29 (+1.37%)
As of: Sep 30, 2026 · 3:55 PM EDT

Pelthos Therapeutics (PTHS) Debt Ratio (2022 - 2026)

Updated

Pelthos Therapeutics' Debt Ratio was 0.19 in Q2 2026, up 20.8% from 0.16 a year earlier and up 6.8% from the prior quarter.

Analysis

Pelthos Therapeutics (PTHS) Debt Ratio (2022 - 2026) Analysis & Trends

For FY2024, Debt Ratio at Pelthos Therapeutics came in at 1.69, down 78.2% from FY2023.

  • In earlier years, Debt Ratio was 7.78 in FY2023 (+308.9%) and 1.90 in FY2022.
  • The Q2 2026 figure marks the highest quarterly Debt Ratio since Q4 2024.
  • Compared with a year earlier, Debt Ratio was higher in three of the last four quarters, with growth averaging 46.1%.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 0.24
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 0.52
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 0.42
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 0.31
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 0.00
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 0.60
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Pelthos Therapeutics 78.87 Mn -9.52 Mn 11.99 Mn 0.19
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.19
Mar 31, 2026 0.18
Jun 30, 2025 0.16
Mar 31, 2025 0.14
Dec 31, 2024 1.69
Sep 30, 2024 0.06
Jun 30, 2024 0.05
Dec 31, 2023 7.78
Dec 31, 2022 1.90
API Access

Pelthos Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=PTHS&period=max&api_key=YOUR_API_KEY